Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing

References

• Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012). Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1 forced mitotic entry by WEE1 inhibition. Cancer Discovery, 2(6), 524–539. https://doi.org/10.1158/2159-8290.CD-11-0320
   PubMed Web of Science ®Google Scholar
• Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Chandrasekaran, J., Kanekar, S., Dagamajalu, S., Modi, P., Gopinathan, K., Raju, R., Prasad, T.K., & Balaya, R. D. A. (2023). Computational design of Checkpoint Kinase-1 (CHK-1) inhibitors for cancer therapy. Preprint (Version 1). Research Square. https://doi.org/10.21203/rs.3.rs-2414645/v1
   Google Scholar
• De Witt Hamer, P. C., Van Tilborg, A. A., Eijk, P. P., Sminia, P., Troost, D., Van Noorden, C. J., Ylstra, B., & Leenstra, S. (2008). The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene, 27(14), 2091–2096. https://doi.org/10.1038/sj.onc.1210850
   PubMed Web of Science ®Google Scholar
• Gopalakrishna, K. P., Gopinathan, K., DAB, R., Kanekar, S., Pavadai, P., & Chandrasekaran, J. (2023). Computational design of Novel Casein kinase 2 small molecule inhibitors for cancer therapy. Preprint (Version 1). Research Square. https://doi.org/10.21203/rs.3.rs-2434417/v1
   Google Scholar
• Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., Freshwater, T., Beijnen, J. H., & Schellens, J. H. M. (2016). Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(36), 4354–4361. https://doi.org/10.1200/JCO.2016.67.5942
   PubMed Web of Science ®Google Scholar
• Liu, C., Yin, J., Yao, J., Xu, Z., Tao, Y., & Zhang, H. (2020). Pharmacophore-based virtual screening toward the discovery of novel anti-echinococcal compounds. Frontiers in Cellular and Infection Microbiology, 10, 118. https://doi.org/10.3389/fcimb.2020.00118
   PubMed Web of Science ®Google Scholar
• Macalino, S. J., Gosu, V., Hong, S., & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. Archives of Pharmacal Research, 38(9), 1686–1701. https://doi.org/10.1007/s12272-015-0640-5
   PubMed Web of Science ®Google Scholar
• Magnussen, G. I., Holm, R., Emilsen, E., Rosnes, A. K., Slipicevic, A., & Flørenes, V. A. (2012). High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. PLoS One, 7(6), e38254. https://doi.org/10.1371/journal.pone.0038254
   PubMed Web of Science ®Google Scholar
• Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Mueller, D., Bakken, K. K., Carlson, B. L., Schroeder, M. A., Evans, D. L., Lou, Z., Decker, P. A., Eckel-Passow, J. E., Pucci, V., Ma, B., Shumway, S. D., Elmquist, W. F., Agar, N. Y. R., & Sarkaria, J. N. (2015). The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood–brain barrier in glioblastoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21(8), 1916–1924. https://doi.org/10.1158/1078-0432.CCR-14-2588
   PubMed Web of Science ®Google Scholar
• Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E., & Mirimanoff, R. O, National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Verma, V. A., Meti, R. S., Saundane, A. R., Londonkar, R., Shinde, V. M., Vennapu, D. R., & Shamrao, R. (2023). Synthesis, E-pharmacophore, molecular docking studies with SARS-CoV-2 protease, their biological properties and DFT calculation of some new indolo [3, 2-c] isoquinoiline hybrids. Polycyclic Aromatic Compounds, 43(1), 80–101. https://doi.org/10.1080/10406638.2021.2009527
   Web of Science ®Google Scholar
• Vriend, L. E., Hamer, P. C., Van Noorden, C. J., & Würdinger, T. (2013). WEE1 inhibition and genomic instability in cancer. Biochimica et Biophysica Acta, 1836(2), 227–235. https://doi.org/10.1016/j.bbcan.2013.05.002
   PubMed Web of Science ®Google Scholar
• Yang, T., Li, Z., Chen, Y., Feng, D., Wang, G., Fu, Z., Ding, X., Tan, X., Zhao, J., Luo, X., Chen, K., Jiang, H., & Zheng, M. (2021). DrugSpaceX: A large screenable and synthetically tractable database extending drug space. Nucleic Acids Research, 49(D1), D1170–D1178. https://doi.org/10.1093/nar/gkaa920
   PubMed Web of Science ®Google Scholar
• Zhu, J.-Y., Cuellar, R. A., Berndt, N., Lee, H. E., Olesen, S. H., Martin, M. P., Jensen, J. T., Georg, G. I., & Schönbrunn, E. (2017). Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors. Journal of Medicinal Chemistry, 60(18), 7863–7875. https://doi.org/10.1021/acs.jmedchem.7b00996
   PubMed Web of Science ®Google Scholar